PT749317E - Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade - Google Patents

Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade

Info

Publication number
PT749317E
PT749317E PT95913668T PT95913668T PT749317E PT 749317 E PT749317 E PT 749317E PT 95913668 T PT95913668 T PT 95913668T PT 95913668 T PT95913668 T PT 95913668T PT 749317 E PT749317 E PT 749317E
Authority
PT
Portugal
Prior art keywords
bactericid
proteins
therapeutic applications
permeability induced
dimeric
Prior art date
Application number
PT95913668T
Other languages
English (en)
Inventor
Roger G Little
William Steve Ammons
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Publication of PT749317E publication Critical patent/PT749317E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PT95913668T 1994-03-11 1995-03-13 Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade PT749317E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/212,132 US5447913A (en) 1994-03-11 1994-03-11 Therapeutic uses of bactericidal/permeability-increasing protein dimer products

Publications (1)

Publication Number Publication Date
PT749317E true PT749317E (pt) 2002-11-29

Family

ID=22789691

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95913668T PT749317E (pt) 1994-03-11 1995-03-13 Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade

Country Status (12)

Country Link
US (4) US5447913A (pt)
EP (1) EP0749317B1 (pt)
JP (1) JPH09510217A (pt)
AT (1) ATE218879T1 (pt)
AU (1) AU703134B2 (pt)
CA (1) CA2185155C (pt)
DE (1) DE69527049T2 (pt)
DK (1) DK0749317T3 (pt)
ES (1) ES2180629T3 (pt)
HK (1) HK1014159A1 (pt)
PT (1) PT749317E (pt)
WO (1) WO1995024209A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
CN1112933C (zh) * 1994-01-14 2003-07-02 爱克索马技术有限公司 抗真菌的方法和物质
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5912228A (en) 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
AU730307B2 (en) * 1995-11-14 2001-03-01 Xoma Corporation Bactericidal permeability increasing protein (BPI) for treating conditions associated with corneal injury
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
NZ332720A (en) * 1996-05-10 2000-07-28 Xoma Corp Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
AU736096B2 (en) * 1996-05-23 2001-07-26 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
CA2255865C (en) * 1996-05-24 2008-10-14 The Regents Of The University Of Minnesota Synthesis of soluble beta-sheet forming peptides
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
ATE229812T1 (de) * 1996-11-01 2003-01-15 Xoma Technology Ltd Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US20050159343A1 (en) * 1999-03-26 2005-07-21 Board Of Regents, University Of Texas System Inhibitors of glycosaminoglycans
AU4204200A (en) * 1999-07-12 2001-01-30 Xoma Technology Ltd. Therapeutic uses of bpi protein products for inhibiting H+/K+ atpase activity
CA2397835A1 (en) * 2000-01-20 2001-07-26 Regents Of The University Of Minnesota Polypeptides with therapeutic activity and methods of use
US6686180B2 (en) * 2000-04-04 2004-02-03 Baxter International Inc. Method for the production of bacterial toxins
WO2002055099A2 (en) * 2000-12-01 2002-07-18 Xoma Technology Ltd Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
JP2005536453A (ja) 2002-02-20 2005-12-02 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 部分的なペプチド擬似物及び方法
DK1492874T3 (da) 2002-03-29 2011-03-14 Xoma Technology Ltd Multigene vektorplasmider og fremgangsmåder til forøgelse af ekspressionen af rekombinante polypeptider
US20040037895A1 (en) * 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
KR101367479B1 (ko) * 2008-07-21 2014-03-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 귀 질병 치료를 위한 제어 방출형 항미생물성 조성물 및 방법
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
CN117686438B (zh) * 2024-02-02 2024-05-10 东北大学秦皇岛分校 一种基于红外偏振光的远程材料鉴别方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ATE178652T1 (de) * 1992-05-19 1999-04-15 Xoma Corp Verbessertes verfahren zur herstellung von endotoxinbindungsproteinen
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
DE69428521T2 (de) * 1993-02-02 2002-05-23 Xoma Technology Ltd Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
ES2123134T3 (es) * 1993-03-12 1999-01-01 Xoma Corp Peptidos biologicamente activos de dominios funcionales de la proteina bactericida aumentadora de la permeabilidad y usos de los mismos.
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
EP0690721B1 (en) * 1993-03-12 1998-05-13 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
ES2157981T3 (es) * 1993-03-12 2001-09-01 Xoma Technology Ltd Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad.
AU7330994A (en) * 1993-07-14 1995-02-13 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
NZ275205A (en) * 1993-09-22 1998-03-25 Xoma Corp Use of bactericidal/permeability-increasing protein in treating gram-negative bacterial infection
ATE269099T1 (de) * 1993-10-15 2004-07-15 Xoma Technology Ltd Bpi-protein-produkte für definierte funktionen des reticuloendothelialen systems
ES2179095T3 (es) * 1994-01-14 2003-01-16 Xoma Technology Ltd Metodos y materiales anti bacterias gram positivas.
CN1112933C (zh) * 1994-01-14 2003-07-02 爱克索马技术有限公司 抗真菌的方法和物质
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries

Also Published As

Publication number Publication date
JPH09510217A (ja) 1997-10-14
AU1996995A (en) 1995-09-25
WO1995024209A1 (en) 1995-09-14
ES2180629T3 (es) 2003-02-16
AU703134B2 (en) 1999-03-18
ATE218879T1 (de) 2002-06-15
EP0749317A1 (en) 1996-12-27
CA2185155C (en) 2001-08-14
US5447913A (en) 1995-09-05
DE69527049T2 (de) 2003-03-06
DK0749317T3 (da) 2002-10-07
HK1014159A1 (en) 1999-09-24
US6277821B1 (en) 2001-08-21
DE69527049D1 (de) 2002-07-18
CA2185155A1 (en) 1995-09-14
EP0749317B1 (en) 2002-06-12
US5856302A (en) 1999-01-05
US5703038A (en) 1997-12-30

Similar Documents

Publication Publication Date Title
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
FR13C0021I2 (fr) Conjugates d'exendin-4 et leur utilisation medicale
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
ATE169304T1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
IL101348A0 (en) Polyethylene glycol protein conjugates,their preparation and pharmaceutical compositions containing them
MXPA03001673A (es) Bacteria de acido lactico capaz de reducir una tendencia individual a desarrollar reacciones alergicas.
DE69726741D1 (de) Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten
SE9804614D0 (sv) New peptides and use thereof
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
ATE179211T1 (de) Menschliche il-3-varianten
TR200100637T2 (tr) Yeni doğal ürün türevleri
IT1270618B (it) Proteine ad attivita' antitumorale
GR880100775A (el) Παράγοντας ενεργοποιήσεως ουδετεροφίλων.
DE69013557D1 (de) An Liposome gekuppelte bioaktive Verbindungen und ihre Verwendung in pharmazeutischen Zubereitungen.
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
MX9805065A (es) Nuevos derivados bi-aromaticos del dibenzofurano y su utilizacion en medicina humana o veterinaria asi como en cosmetica.
DE69718047D1 (de) Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
DE69323191D1 (de) Wasserlösliche retinoide
DE59611330D1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
ES2067058T3 (es) Tratamiento de carnes.
FR2679909B1 (fr) Polypeptides aptes a induire in vivo des anticorps inhibant l'invasion de globules rouges par des merozouites de p. falciparum, produits apparentes et leur application comme vaccin.
ITPC930011A0 (it) Composizione cosmetica contenente proteine dello yogurt ed estratto dibetulla, per la reparazione di prootti tricologici.
ITRM940453A0 (it) "uso della proteina p1lsa per la preparazione di un medicamento da utilizzarsi nella terapia di patologie indotte da danni cellulari da agenti fisici, chimici o biologici"